Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.vaccine.2021.06.058 http://scihub22266oqcxt.onion/10.1016/j.vaccine.2021.06.058 34215453!8220987!34215453     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34215453&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Vaccine 2021 ; 39 (32): 4407-4409 Nephropedia Template TP {{tp|p=34215453|t=2021. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration |pdf=|usr=}}{{34215453}} gab.com Text Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration JO: Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=34215453 #FOAvip Two mRNA vaccines for COVID-19, Pfizer-BioNTech and Moderna, are approved for emergency use in the United States. After their approval and dosing in millions of recipients, reports of anaphylaxis began to appear in the Vaccine Adverse Reporting System (VAERS). Here we provide an analysis of the relationship between prior history of allergy and/or anaphylaxis and anaphylaxis rates following the administration of mRNA COVID-19 vaccines. Overall reported incidence of anaphylaxis was estimated to be rare at 4.2 cases per million doses. It appeared that the relative incidence of anaphylaxis following administration of these COVID-19 vaccines was two and seven times higher for recipients with a prior history of allergies and/or anaphylaxis, respectively. This report provides valuable metrics to make evidence-based decisions for subjects with pre-existing allergic conditions receiving a COVID-19 mRNA vaccine. Twit Text FOAVip Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration ????Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=34215453 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34215453 #FOAvip English Wikipedia <ref>{{Cite pmid|34215453}}</ref> Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration #MMPMID34215453 Desai AP; Desai AP; Loomis GJ Vaccine 2021[Jul]; 39 (32): 4407-4409 PMID34215453show ga Two mRNA vaccines for COVID-19, Pfizer-BioNTech and Moderna, are approved for emergency use in the United States. After their approval and dosing in millions of recipients, reports of anaphylaxis began to appear in the Vaccine Adverse Reporting System (VAERS). Here we provide an analysis of the relationship between prior history of allergy and/or anaphylaxis and anaphylaxis rates following the administration of mRNA COVID-19 vaccines. Overall reported incidence of anaphylaxis was estimated to be rare at 4.2 cases per million doses. It appeared that the relative incidence of anaphylaxis following administration of these COVID-19 vaccines was two and seven times higher for recipients with a prior history of allergies and/or anaphylaxis, respectively. This report provides valuable metrics to make evidence-based decisions for subjects with pre-existing allergic conditions receiving a COVID-19 mRNA vaccine. |*Anaphylaxis/chemically induced/epidemiology[MESH] |*COVID-19[MESH] |*Vaccines/adverse effects[MESH] |COVID-19 Vaccines[MESH] |Humans[MESH] |RNA, Messenger/genetics[MESH] |SARS-CoV-2[MESH]Relationship between pre-existing allergies and anaphylactic reactions(epmc).pdf DeepDyve Pubget Overpricing